|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Trimbos JB, Vergote I, Bolis G, et al:
Impact of adjuvant chemotherapy and surgical staging in early-stage
ovarian carcinoma: European Organisation for Research and Treatment
of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl
Cancer Inst. 95:113–125. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kurman RJ and Shih IeM: Molecular
pathogenesis and extraovarian origin of epithelial ovarian cancer -
shifting the paradigm. Hum Pathol. 42:918–931. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hess LM, Rong N, Monahan PO, Gupta P,
Thomaskutty C and Matei D: Continued chemotherapy after complete
response to primary therapy among women with advanced ovarian
cancer: a meta-analysis. Cancer. 116:5251–5260. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin Z, Yang H, Kong Q, et al: USP22
antagonizes p53 transcriptional activation by deubiquitinating
Sirt1 to suppress cell apoptosis and is required for mouse
embryonic development. Mol Cell. 46:484–494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu YL, Jiang SX, Yang YM, Xu H, Liu JL
and Wang XS: USP22 acts as an oncogene by the activation of
BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem
Biophys. 62:229–235. 2012. View Article : Google Scholar
|
|
8
|
Zhang XY, Varthi M, Sykes SM, et al: The
putative cancer stem cell marker USP22 is a subunit of the human
SAGA complex required for activated transcription and cell-cycle
progression. Mol Cell. 29:102–111. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu J, Liu YL, Piao SL, Yang DD, Yang YM
and Cai L: Expression patterns of USP22 and potential targets
BMI-1, PTEN, p-AKT in non-small-cell lung cancer. Lung Cancer.
77:593–599. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Piao S, Liu Y, Hu J, et al: USP22 is
useful as a novel molecular marker for predicting disease
progression and patient prognosis of oral squamous cell carcinoma.
PLoS One. 7:e425402012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Yao L, Zhang X, et al: Elevated
expression of USP22 in correlation with poor prognosis in patients
with invasive breast cancer. J Cancer Res Clin Oncol.
137:1245–1253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Piao S, Ma J, Wang W, et al: Increased
expression of USP22 is associated with disease progression and
patient prognosis of salivary duct carcinoma. Oral Oncol.
49:796–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang DD, Cui BB, Sun LY, et al: The
co-expression of USP22 and BMI-1 may promote cancer progression and
predict therapy failure in gastric carcinoma. Cell Biochem Biophys.
61:703–710. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu H, Liu YL, Yang YM and Dong XS:
Knock-down of ubiquitin-specific protease 22 by micro-RNA
interference inhibits colorectal cancer growth. Int J Colorectal
Dis. 27:21–30. 2012. View Article : Google Scholar
|
|
15
|
Tian M and Schiemann WP: The TGF-β paradox
in human cancer: an update. Future Oncol. 5:259–271. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bierie B and Moses HL: Tumour
microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer.
Nat Rev Cancer. 6:506–520. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wenner CE and Yan S: Biphasic role of
TGF-β1 in signal transduction and crosstalk. J Cell Physiol.
196:42–50. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Principe DR, Doll JA, Bauer J, et al:
TGF-β: duality of function between tumor prevention and
carcinogenesis. J Natl Cancer Inst. 106:djt3692014. View Article : Google Scholar
|
|
19
|
Cho MS, Bottsford-Miller J, Vasquez HG, et
al: Platelets increase the proliferation of ovarian cancer cells.
Blood. 120:4869–4872. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cai J, Tang H, Xu L, et al: Fibroblasts in
omentum activated by tumor cells promote ovarian cancer growth,
adhesion and invasiveness. Carcinogenesis. 33:20–29. 2012.
View Article : Google Scholar
|
|
21
|
Yang Y, Kitagaki J, Wang H, Hou DX and
Perantoni AO: Targeting the ubiquitin-proteasome system for cancer
therapy. Cancer Sci. 100:24–28. 2009. View Article : Google Scholar :
|
|
22
|
Song L and Rape M: Reverse the curse - the
role of deubiquitination in cell cycle control. Curr Opin Cell
Biol. 20:156–163. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen M, Schmitt S, Buac D and Dou QP:
Targeting the ubiquitin-proteasome system for cancer therapy.
Expert Opin Ther Targets. 17:1091–1108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hussain S, Zhang Y and Galardy PJ: DUBs
and cancer: the role of deubiquitinating enzymes as oncogenes,
non-oncogenes and tumor suppressors. Cell Cycle. 8:1688–1697. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kapoor S: Usp22 and its evolving role in
systemic carcinogenesis. Lung Cancer. 79:1912013. View Article : Google Scholar
|
|
26
|
Schrecengost RS, Dean JL, Goodwin JF, et
al: USP22 regulates oncogenic signaling pathways to drive lethal
cancer progression. Cancer Res. 74:272–286. 2014. View Article : Google Scholar
|
|
27
|
Liu YL, Yang YM, Xu H and Dong XS:
Increased expression of ubiquitin-specific protease 22 can promote
cancer progression and predict therapy failure in human colorectal
cancer. J Gastroenterol Hepatol. 25:1800–1805. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li J, Wang Z and Li Y: USP22 nuclear
expression is significantly associated with progression and
unfavorable clinical outcome in human esophageal squamous cell
carcinoma. J Cancer Res Clin Oncol. 138:1291–1297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kajdaniuk D, Marek B, Borgiel-Marek H and
Kos-Kudla B: Transforming growth factor β1 (TGFβ1) in physiology
and pathology. Endokrynol Pol. 64:384–396. 2013. View Article : Google Scholar
|
|
30
|
Moses H and Barcellos-Hoff MH: TGF-β
biology in mammary development and breast cancer. Cold Spring Harb
Perspect Biol. 3:a0032772011. View Article : Google Scholar
|
|
31
|
Anscher MS: Targeting the TGF-β1 pathway
to prevent normal tissue injury after cancer therapy. Oncologist.
15:350–359. 2010. View Article : Google Scholar
|
|
32
|
Lv L, Xiao XY, Gu ZH, Zeng FQ, Huang LQ
and Jiang GS: Silencing USP22 by asymmetric structure of
interfering RNA inhibits proliferation and induces cell cycle
arrest in bladder cancer cells. Mol Cell Biochem. 346:11–21. 2011.
View Article : Google Scholar
|
